PowerUp Acquisition Corp. appoints Kyle Campbell as independent Class III director

Aspire Biopharma Holdings, Inc.

Kyle Campbell appointed as Class III director effective May 16, 2022.
Board determined Campbell is independent under Nasdaq and SEC rules; joins Audit Committee.
Campbell is senior analyst at Greenhaven Road Capital and former CFO of a family office.
No family relationships or transactions with the company exist.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyle Campbell

Class III director

ASBP · Aspire Biopharma Holdings, Inc.

Effective: 2022-05-16
Filed: May 19, 2022, 7:59 PM ET

Effective May 16, 2022, the board of directors (the “Board”) of PowerUp Acquisition Corp., a Cayman Islands exempted company (the “Company”), appointed Kyle Campbell, as a Class III director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kyle Campbell was appointed as Class III director at Aspire Biopharma Holdings, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Effective May 16, 2022, the board of directors (the “Board”) of PowerUp Acquisition Corp., a Cayman Islands exempted company (the “Company”), appointed Kyle Campbell, as a Class III director of the Company.

View on SEC.gov

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-062870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.